http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Nov 2025 18:16:41 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html <p>Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).</p> <p>The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.</p> <p>Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie http://www.streetinsider.com/Board+Changes/Elanco+executive+joins+Neurizon+board+as+observer/25672209.html Wed, 26 Nov 2025 18:16:41 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>Nov. 26, 2025</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ &amp; NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms <person>Justine Conway</person> as a <span>Board Observer</span>. <person>Ms Conway</person> currently serves as Global Head of Business Development at <span value="NYSE:ELAN" idsrc="xmltag.org" >Elanco Animal Health</span> ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</p> <p>The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. http://www.streetinsider.com/Press+Releases/Elanco+executive+appointed+as+Neurizon%27s+Board+Observer/25672208.html Wed, 26 Nov 2025 18:15:00 -0500 2 2025 A.14871017 A.18696199 ELAN NUZ NUZOA NUZTF O.00674867 O.00756621 O.05710206 O.10590994 PAA